Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1534https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-15-1534
Retrieved on: 
Tuesday, April 9, 2024
Information
Tags: 
Eurostat, Diagnosis, Civil service commission, Speech, X chromosome, Brain, Medicine, MECP2, Disease, Laxative, Seizure, Nervous system, Patient, Chromosome, Committee, Knowledge, Constipation, Regulation, EMA, IRIS, Rett syndrome, Male, Intellectual disability, Clinical trial, European, COMP, Safety, European Commission, Marketing, Parent, Syndrome, DSM-IV codes, Anatomical pathology, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, EC, ICELAND, EU, IRELAND, NORWAY, UNITED KINGDOM, UNITED STATES, LIECHTENSTEIN
Summary
Key Points: 


Orphan designation: Glycyl-L-2-methylprolyl-L-glutamic acid Treatment of Rett syndrome, 10/08/2015 Positive

Copyright: 
2024 European Medicines Agency. All Rights Reserved.